PUBLISHER: DelveInsight | PRODUCT CODE: 1147333
PUBLISHER: DelveInsight | PRODUCT CODE: 1147333
DelveInsight's " Glioblastoma Multiforme Market - Market Insights, Epidemiology and Market Forecast- 2032" report delivers an in-depth understanding of the GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, the EU-4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.
GBM market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM market size from 2019 to 2032. The report also covers current GBM treatment practice/algorithm, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.
Study Period: 2019-2032.
GBM is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. GBM is often located in a region of the forebrain known as the cerebrum, which controls some of the most advanced process such as speech and emotions. The exact underlying cause of GBM is unknown. Some cases may develop from existing, low-grade astrocytomas (malignant transformation) or they may occur without any evidence of a previous tumor (de novo).
The diagnosis of GBM includes neurological exams (this exam tests vision, hearing, speech, strength, sensation, balance, coordination, reflexes and the ability to think and remember), angiograms, magnetic resonance imaging (MRI) and computerized tomography (CT), surgical biopsy and others.
Treatment for GBM usually includes a combination of surgery, chemotherapy, radiation, stereotactic radiosurgery and Tumor treatment fields (TTF). Chemotherapy includes Carmustine (BCNU), Lomustine (CCNU), or Gleostine (Generic), Gliadel wafer (biodegradable discs infused with BCNU), Temozolomide (Temodar) Cisplatin, Carboplatin, Etoposide and Irinotecan. They may be given as a single agent or in combination i.e. PCV (Procarbazine, CCNU, and Vincristine), Carboplatin/ Etoposide. The drugs most commonly used to treat brain tumors are temozolomide (Temodar) and bevacizumab (Avastin).
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Diagnosed Incident Population of GBM, Gender-specific Diagnosed Incidence of GBM, Type-specific Diagnosed Incidence of GBM, Age-specific Diagnosed Incidence of GBM, Diagnosed Incident Population based on Primary Site of GBM, and Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the 7MM market covering the United States, EU-4 countries (Germany, France, Italy, and Spain), the United Kingdom and Japan from 2019 to 2032.
This section provides glimpse of the GBM epidemiology in the 7MM.
Drug chapter segment of the GBM report encloses the detailed analysis of GBM marketed drugs and emerging (Phase-III and Phase II and Phase I/II) pipeline drugs. It also helps to understand the GBM clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Avastin (Bevacizumab) is a recombinant humanized monoclonal IgG1 antibody, which acts as angiogenesis inhibitor by blocking its target, vascular endothelial growth factor (VEGF). Bevacizumab binds to the vascular endothelial growth factor (VEGF) with its receptor VEGFR-1 and VEGFR-2, which are present on the surface of endothelial cells. In December 2017, the US FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent GBM that has progressed following prior therapy.
The active pharmaceutical ingredient in Temodar/Temodal, is an imidazotetrazine derivative of the alkylating agent dacarbazine. Temozolomide is used for the treatment of several brain cancer forms, e.g., as a second-line treatment for astrocytoma and as a first-line treatment for GBM. The therapeutic benefit of temozolomide is due to its ability to alkylate/methylate DNA. In July 2006, the Japan Ministry of Health, Labor and Welfare (MHLW) approved Temodal (R) (temozolomide) Capsules for the treatment of malignant glioma.
Note: Detailed Current therapies assessment will be provided in the full report of GBM.
Ofranergene obadenovec (VB-111) is a first-in-class, targeted anticancer gene-therapy agent that is being developed by VBL Therapeutics to treat a wide range of solid tumors such as GBM. It is a non-replicating adenovirus 5 (Ad-5, El-deleted) carrying a proapoptotic human Fas-chimera transgene that targets angiogenic blood vessels and leads to vascular disruption. The drug has been rewarded Orphan Drug Designation from both US FDA and EMA for the treatment of patients with GBM. In addition, it has also been granted Fast Track Designation by the US FDA for prolongation of survival in patients with rGBM. Currently, the drug has completed phase III stage of clinical development for the patients with rGBM. In November 2017, VBL Therapeutics signed an exclusive license agreement with NanoCarrier for the development, commercialization, and supply of ofranergene obadenovec (VB-111) in Japan.
Trans Sodium Crocetinate (TSC), being investigated by Diffusion Pharmaceuticals, is a first-in-class small molecule that, by its novel proprietary mechanism, safely reoxygenates oxygen-deprived tissue. It can act alone or with other treatments and presents opportunities in unmet medical needs across several markets. It can be used to enhance the cancer-killing power of radiation and chemotherapy for treating patients with GBM.
Selinexor (KPT-330) is a first-in-class, oral Selective Inhibitor of Nuclear Export/SINE compound in development by Karyopharm Therapeutics. It functions by binding with and inhibiting the nuclear export protein XPO1 (also called CRM1), leading to the accumulation of tumor suppressor proteins in the cell nucleus, which subsequently reinitiates and amplifies their tumor suppressor function; this is supposed to lead to the selective induction of apoptosis in cancer cells, while largely sparing normal cells. The drug has been approved with a brand name Xpovio for patients in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody. The phase II (KING) study was terminated due to sponsor decision.
VBI-1901 is a cancer vaccine that VBI Vaccines has designed to treat GBM and medulloblastoma, which are two types of brain tumors. It is designed to kill GBM and medulloblastoma tumor cells infected with cytomegalovirus or CMV. While the immune system already targets cells infected by viruses, VBI-1901's goal is to boost their immune response such viruses. CMV inside tumor cells generate proteins called viral antigens that travel to the cells' surface. Currently, the vaccine is in phase I/II stage of clinical development for the patients with recurrent GBM and the company expects to initiate a randomized, controlled clinical study with registration potential in the fourth quarter of 2021. Recently, in June 2021, the company was granted Fast track designation by the FDA for VBI-1901 for the treatment of recurrent GBM.
Immunomic Therapeutics (ITI) is developing ITI-1000 (pp65 DC vaccine), which is a cancer cell vaccine consisting of autologous dendritic cells (DCs) loaded with mRNA encoding the human cytomegalovirus (CMV) matrix protein pp65 as a fusion protein with the short lysosome-associated membrane protein (shLAMP), with potential immunostimulatory and antineoplastic activities. ITI-1000 is currently being investigated in a phase II ATTAC-II trial for Glioblastoma Multiforme, Glioblastoma, Malignant Glioma, Astrocytoma, Grade IV, and GBM and is funded by the National Cancer Institute.
Note: Detailed emerging therapies assessment will be provided in the final report.
Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.
The first step in treating glioblastoma is a surgical procedure to make a diagnosis, to relieve pressure on the brain, and to remove as much tumor as possible safely. Glioblastoma surgery is performed to achieve a "maximum safe resection," or removing as much of the tumor as possible without causing lasting neurological damage.
It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.
The GBM pipeline possessed multiple potential drugs in late- and mid-stage developments to be launched shortly. Key players involved in robust research and development include Paxalisib (GDC-0084): Kazia Therapeutics, LAM561: Laminar Pharmaceuticals, Tasa-denoturev (DNX-2401): DNAtrix and, others are some of the major players that are going to alter the market dynamics in the coming years.
This section includes a glimpse of the GBM 7MM market.
The total market size of GBM in the United States is expected to increase with a CAGR of 13.1% during the study period (2019-2032).
The total market size of GBM in EU-4, the UK is expected to increase with a CAGR of 13.5% during the study period (2019-2032).
The total market size of GBM in Japan is expected to increase with a CAGR of 10.4% during the study period (2019-2032).
This section focusses on the rate of uptake of the potential drugs expected to get launched in the market during the study period 2019-2032. The analysis covers GBM market uptake by drugs; patient uptake by therapies; and sales of each drug. For example- Kintara Therapeutics 'VAL-083' is a DNA-targeting agent, in three distinct biomarker-driven GMB patient populations. VAL-083 can cross the blood-brain barrier (BBB), has biological and tumor affecting activity against a range of cancers, including GBM and ovarian cancer. As per our analysis VAL-083, drug uptake in the US is expected to be medium-fast with peak share of 12%, years to peak would be 7 years in first line, whereas in second-line peak share is estimated to 5.5%.
The report provides insights into different therapeutic candidates in Phase III, Phase II and Phase I/II stage. It also analyzes key players involved in developing targeted therapeutics.
The report covers the detailed information of collaborations, acquisition and merger, licensing and patent details for GBM emerging therapies.
To keep up with current market trends, we take KOLs and SME's opinion working in the domain through primary research to fill the data gaps and validate our secondary research. Some of the leaders like Chief Executive Officer, VBL Therapeutics, Chief executive officer, DNAtrix, Chief Medical Officer, VBI Vaccines, Chief Medical Officer, Kazia Therapeutics and others. Their opinion helps to understand and validate current and emerging therapies treatment patterns or GBM market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
We perform competitive and market Intelligence analysis of the GBM market by using various competitive intelligence tools that include-SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.